drugset / Trial / NCT02439957
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
RandomizedParallel-groupTriple-blindPrevention
Summary
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy.
Timeline
- Start
- 2015-09
- Primary completion
- 2016-05-15
- Completion
- 2016-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brincidofovir | Other / unclassified | 100 mg | Oral |
| Comparator | Valganciclovir | Small molecule | 900 mg | Oral |